All In Biotech

Drug Trial Radar · NCT07943000

Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 2029

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
University of Vermont Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies. Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental. Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit. Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.

Conditions

  • Healthy Volunteers
  • Redox Biology

Interventions

  • ethacrynic acidDrug

    Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Peripheral Blood Mononuclear Cell GST ActivityTime frame: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.